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AbstrACt
Introduction Self-harm in prison is a major public health 
concern. Less than 5% of UK prisoners are women, but 
they carry out more than a fifth of prison self-harm. 
Scars resulting from self-harm can be traumatising and 
stigmatising, yet there has been little focus on recovery 
of women prisoners with self-harm scarring. Medical skin 
camouflage (MSC) clinics treat individuals with disfiguring 
skin conditions, with evidence of improved well-being, 
self-esteem and social interactions. Only one community 
study has piloted the use of MSC for self-harm scarring.
Methods and analysis We describe an acceptability and 
feasibility pilot randomised controlled trial; the first to 
examine MSC for women prisoners who self-harm. We aim 
to randomise 20–25 women prisoners to a 6-week MSC 
intervention and 20–25 to a waitlist control (to receive the 
MSC after the study period). We aim to train at least 6–10 
long-term prisoners with personal experience of self-harm 
to deliver the intervention. Before and after intervention, 
we will pilot collection of women-centred outcomes, 
including quality of life, well-being and self-esteem. We 
will pilot collection of self-harm incidents during the 
intervention, resources used to manage/treat self-harm 
and follow-up of women at 12 weeks from baseline. Data 
on recruitment, retention and dropout will be recorded. 
We aim for the acceptability of the intervention to prison 
staff and women prisoners to be explored in qualitative 
interviews and focus groups.
Ethics and dissemination Ethical approval for COVER 
has been granted by the North East–York Research 
Ethics Committee (REC) for phases 1 and 2 (reference: 
16/NE/0030) and West of Scotland REC 3 for phases 
3 and 4 (reference: 16/WS/0155). Informed consent 
will be the primary consideration; it will be made clear 
that participation will have no effect on life in prison 
or eligibility for parole. Due to the nature of the study, 
disclosures of serious self-harm may need to be reported 
to prison officials. We aim for findings to be disseminated 
via events at the study prison, presentations at national/
international conferences, journal publications, prison 
governor meetings and university/National Health Service 
trust communications.
trial registration number NCT02638974; Pre-results.
IntroduCtIon 
self-harm in women’s prisons
Self-harm is defined as ‘intentional self-poi-
soning or injury, irrespective of the apparent 
purpose of the act.’1 The most common 
methods for self-harm in women’s prisons are 
cutting and scratching followed by self-stran-
gulation.2 This complex behaviour is an 
increasing public health concern, not least 
because of its association with acute psycho-
logical distress and increased suicide risk.2 3 
Self-harm is extremely prevalent and 
increasing in UK prisons. In the 12 months 
to December 2016 there were 7657 incidents 
of self-harm in female prisons, an increase 
of 4% on the previous year.4 This is a rate of 
1987 self-harm incidents per 1000 prisoners. 
Although women make up approximately 5% 
of the UK prison population, they are respon-
sible for around a fifth of all prison self-harm.4
strengths and limitations of this study
 ► COVER is the first pilot randomised controlled trial of 
the use of medical skin camouflage for women who 
self-harm in prison.
 ► The study has been codesigned with experts-by-ex-
perience to test the delivery of a peer-led 
intervention.
 ► As a pilot, the sample size for the study is small, 
however, the research is designed to gather data 
on the feasibility and acceptability of delivering the 
intervention in prison rather than the efficacy of the 
intervention.
 ► The study will take place in one prison within the 
women’s estate.
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Research has shown that living with disfigurement 
from non-self-harm causes can have long-term physical 
and psychosocial effects, including reduced social inter-
action, increased social anxiety and reduced quality of 
life.5 6 Furthermore, living with scars can be challenging in 
a society which values physical attractiveness.7 8 It is likely 
that women prisoners with self-harm scarring experience 
similar psychosocial difficulties, for example, low self-es-
teem and interpersonal problems. These may be exacer-
bated by guilt and shame that women may feel because 
of their self-inflicted injuries.9 There are, however, indi-
viduals who feel ambivalent about their self-harm scars, 
and while they may attempt to conceal scars in certain 
contexts, some feel confident and comfortable with their 
physical appearance.10
Medical skin camouflage
Medical skin camouflage (MSC) uses British National 
Formulary-listed preparations to reduce the visibility of 
scarring or disfigurement,11 with the potential to restore 
self-esteem, and aid recovery.12–14 Products include 
skin-matched creams and powders that are waterproof 
and opaque and allow adherence to textured skin. All 
the products are ‘borderline prescription’ products that 
are available on National Health Service (NHS) prescrip-
tion at each prescriber’s discretion. A systematic review 
of the use of MSC in prisons yielded no available studies. 
Only a handful of published studies have evaluated the 
emotional/psychological benefits of MSC and all were in 
dermatological diseases or burns scarring. They report 
significant psychological benefit, improved social and 
sexual relationships and improved employability.8 15 16 
Despite these potential benefits, few services offer MSC 
for self-harm scarring.17
There has been little focus on how prisoners feel about 
their self-harm scars and no formally evaluated interven-
tions to help women cope with any related psychosocial 
difficulties. This is the first study to formally deliver and 
evaluate an MSC intervention in a women’s prison. Poten-
tial benefits of the intervention may include (1) increased 
self-esteem, confidence and quality of life; (2) empow-
ering women to take part in work and social activities they 
might otherwise avoid; and (3) enhancing the strategies 
and interventions that prison staff have to work with self-
harm.18 Previous work by the research team has shown 
that there is a difficult relationship between prison staff 
and prisoners who self-harm and that staff feel restricted 
in how to help women.19 This intervention may help staff 
to support women with self-harm scars and promote posi-
tive staff attitudes about self-harm and its management.
This study has been developed in collaboration with 
staff from North West Boroughs Healthcare  NHS Foun-
dation Trust (NWBP) who recently piloted an innovative 
camouflage service for service users with self-harm scars.20 
The 6-month pilot found that 95% of young people who 
used the MSC experienced improved confidence and 
ability to engage in activities.20 To our knowledge, this is 
the first time that MSC has been evaluated in a mental 
health service and provided as part of a recovery package. 
The NWBP MSC service continues to be run in partner-
ship with Changing Faces, a registered charity that uses 
volunteers to teach the MSC techniques to people in 
the community. This feasibility and acceptability study 
would provide insight into any benefits of using MSC in 
women’s prisons and also any downsides, risks or unin-
tended consequences.
Phases 1 and 2
The MSC intervention and protocol used in our study 
were informed by the Changing Faces MSC training mate-
rials21 and modified in phases 1 and 2 of the project. Phase 
1 involved one focus group, with women prisoners with 
experience of self-harm (n=10) and one with prison staff 
(n=10). Both groups were conducted in Safer Custody 
meeting rooms and lasted between 60 and 90 min. The 
staff focus group explored and refined practical aspects 
of delivering MSC in the prison, including details of how 
participants would be recruited, where MSC clinics would 
be held and whether any MSC items would be unsuit-
able for prison use. The focus group with women pris-
oners helped to select the set of women-centred outcome 
measures and discussed their thoughts on long-term 
prisoners delivering the intervention. Women said they 
would prefer to be trained by other prisoners, particularly 
other women who have self-harmed. The rationale for 
recruiting long-term prisoners to deliver the intervention 
was to improve the sustainability of the intervention since 
they are likely to remain in the prison for a long time 
and can therefore continue training women to use MSC. 
Women also discussed the idea of completing a weekly 
diary; they thought this would be a good way of recording 
any thoughts or incidents of self-harm and some women 
had used a diary previously. Phase 2 involved adapting the 
MSC treatment intervention based on these focus groups, 
and producing the training and intervention protocols. 
The full analysis of the focus groups will be reported in a 
separate paper.
Study aims
1. To evaluate the feasibility and acceptability of a ran-
domised controlled trial (RCT) of MSC for women 
prisoners with self-harm scarring.
2. To assess the feasibility and acceptability of long-term 
prisoners delivering the MSC intervention.
3. To test the feasibility and acceptability of collecting a 
set of women-centred outcome measures before and 
after intervention, as well as a weekly self-harm diary.
4. To pilot follow-up of women at 12 weeks after baseline.
5. To test the feasibility and acceptability of collecting re-
source use data relating to self-harm incidents.
MEthods And AnAlysIs
design
This study is a feasibility pilot of an RCT, incorporating a 
qualitative component to assess the acceptability of MSC 
to women prisoners and prison staff. The study is taking 
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place in one UK closed women’s prison. The research 
is funded by the National Institute for Health Research 
(NIHR) Research for Patient Benefit Programme 
(PB-PG-1013–32075). It was approved by North East–York 
Research Ethics Committee (REC) for phases 1 and 2 
(reference: 16/NE/0030) and West of Scotland REC for 
phases 3 and 4 (reference: 16/WS/0155). The current 
protocol version is Version 6 (17/05/2017).
Patient and public involvement
At the development phase of the research, a patient and 
public involvement group was conducted in one women’s 
prison using a Patient and Public Involvement bursary 
from the NIHR Research Design Service North West. 
During this group women from the prison, who had self-
harm scarring, contributed towards the research topic 
development through discussion of the possible impact 
of MSC. This informed the outcome measures for the 
research and the topic guides/interview schedules for 
the qualitative work. In phase 1 of the research, women 
in prison with self-harm scarring helped refine the design 
of the research assessing the burden of involvement in 
an RCT.
Two experts-by-experience joined the research team 
at the start of the research and contributed towards the 
design of all the materials for participants. In phase 3, one 
of these experts-by-experience will help train the long-
term prisoners to be MSC practitioners having agreed 
to allow the women to practice application of the MSC 
on their self-harm scars. Another of our experts-by-expe-
rience, who is a trained qualitative researcher, analysed 
the phase 1 focus group data and will cofacilitate the staff 
focus group at the end of the research. A current prisoner, 
who works in Safer Custody, has agreed to help organise 
the participants’ appointments in the prison and will sit 
on the project steering group. At the end of the research, 
our experts-by-experience will help us design a dissem-
ination event for the women in prison that will involve 
presentations on the research outcomes. A plain English 
summary of the research will also be provided to women 
in the prison. We will also disseminate the research on the 
closed prison radio system.
sample size
Over 6 months (January 2017 to May 2017), we aim to 
recruit at least 6–10 long-term women prisoners to be 
trained in MSC. These women will then deliver the inter-
vention to trial participants. The long-term prisoners will 
not be participants in the RCT, but will instead form an 
integral part of the research team delivering the interven-
tion to the RCT participants.
Over 17 months (January 2017 to May 2018) we aim 
to recruit and consent 40–50 women prisoners to be 
randomised to receive either MSC or ‘treatment as usual’ 
in a waitlist control (to receive the MSC after the study 
period) design. Based on previous research22 and recent 
figures from the study prison, we estimate that there will 
be around five to six eligible women per month. The 
sample size is based on a prediction that approximately 
half of these eligible women will be interested in the 
research.
Participants and recruitment procedures
Recruitment procedures and advertisement strategies 
have been informed by the phase 1 focus groups. The 
research team will advertise the research at Safer Custody 
meetings attended by women prisoners. Leaflets and 
posters will be distributed to our local collaborators in 
the prison for display in different locations around the 
prison. Women will inform the local collaborators if they 
are interested in participating. We have one member of 
Safer Custody staff collaborating with the researchers and 
a woman prisoner from the Safer Custody team organ-
ising the research appointments. Prison staff will assess 
all volunteers to determine whether they would pose a 
risk to the researchers or other participants. Staff will also 
check the woman’s sentence length to ensure she has 
enough time remaining on her sentence to take part in 
the study. In addition, healthcare staff will review the list 
of women to assess whether there are any health reasons 
why they might not be safe to participate. This has been 
usual practice across our decade of prisoner participation 
in research.
Vetted/screened women will be provided with an 
information sheet and offered the opportunity for 
the research team to visit, read through the sheet and 
answer any questions. Consent for the research will be 
agreed at least 24 hours after the information sheet has 
been read.
Inclusion/exclusion criteria
Phase 3
We aim to recruit 6–10 long-term prisoners with at least 
10 years or more left on their sentence and who have 
experience of self-harm.
Discussions with prison staff suggested that the most suit-
able long-term women would be those who already hold 
a position of responsibility in the prison, for example, a 
peer supporter or trained Samaritan listener.
Phase 4
We aim to recruit 40–50 women prisoners screened for 
date of release, with sufficient time left on their sentence 
to complete the intervention period. The women will 
have self-harm scarring anywhere on their body that they 
are happy to show to others, with at least some closed 
wounds (to allow the MSC to be applied).
All participants (phases 3 and 4) will be aged 18 or 
older and able to give written informed consent. Capacity 
to consent will be assessed by the experienced researchers 
(HM and KG) in collaboration with Safer Custody and 
Mental Health Care contacts in the prison. Participants 
will be excluded from the study if they are unable to 
provide written informed consent, or if they pose a risk to 
researchers (as assessed by the prison).
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randomisation
In phase 4 internet randomisation (using an inter-
net-based programme to randomise participants; www. 
sealedenvelope. com) will be carried out by the non-blind 
members of the research team, KG or HM, to allocate 
eligible women to MSC or waitlist control. Women in the 
waitlist group would receive one skin-matched prescrip-
tion of MSC at the end of the research. Waitlist control 
has been chosen as the comparator to give all participants 
an opportunity to use the MSC. Participants randomised 
to the waitlist control would be aware of their allocation 
(figure 1).
the intervention: MsC for self-harm scarring (adapted for 
delivery in a women’s prison)
Development
Outcomes of the phase 1 focus groups informed the 
development of the MSC intervention materials. In addi-
tion, two service user researchers (FE and TM) provided 
guidance to the research team, focusing on whether the 
intervention materials were suitable in terms of read-
ability and sensitivity.
The intervention package consists of the training 
manual and four additional documents. The main 
training manual has been adapted from training manuals 
used by Changing Faces.21 The adapted materials have 
been reviewed by a representative from the charity, to 
ensure that all key learning and safety points are covered.
Manual content
The 34-page training manual has 13 sections that are 
listed and briefly described in table 1.
Accompanying documents
1. A single sheet of key learning points for long-term pris-
oners covering safety issues such as how to protect tri-
al participants, for example, breaking confidentiality 
if a woman discloses something which suggests she or 
someone else is at risk of harm.
2. A monitoring sheet for long-term prisoners to be used 
in weekly meetings with the research team. The form 
will help identify whether any further training or sup-
port is required.
3. An appointment checklist for long-term prisoners 
breaking down the 14 core steps in an MSC appoint-
ment, from laying out the kit, to completing a prescrip-
tion record card.
4. A DO’s and DON’Ts sheet for trial participants: this 
covers reminder points, including those related to safe-
ty and hygiene (eg, always keep lids on the products) 
and some rules relating to continued participation in 
the trial (eg, don’t trade or share the products as only 
one prescription will be provided, added at the request 
of prison staff).
delivery of the intervention
Three stages of delivery: (1) training sessions for long-
term prisoners, (2) skin camouflage clinics run by 
long-term prisoners for trial participants, (3) prescription 
of MSC products by prison healthcare.
1. Members of the research team aim to deliver a half-
day group training session to 6–10 long-term women 
prisoners. During this session, the research team will 
work through the training manual, answering any 
questions and giving practical demonstrations of co-
lour matching, application techniques and powder-
ing. Participants will participate in practical activities 
to ensure that they have understood the training and 
are competent in MSC. There is scope for the train-
ing time to be extended if the women require more 
practice.
2. The aim is that regular skin camouflage appointments 
will be run by the trained long-term prisoners. The 
appointments will be held during the core prison 
day and will not interfere with the women’s income. 
All participants will be seen individually for 1 hour; 
the intervention group will be seen as soon as possi-
ble after they have been randomised and the waitlist 
control group will be seen after they have completed 
their 12-week follow-up. During this appointment, the 
long-term prisoner will provide the woman with infor-
mation about the MSC creams and powders; including 
allergy checks to ensure the woman can safely use the 
products. The long-term prisoner will then perform 
a colour match for the participant and demonstrate 
the application techniques. The participant will then 
practise applying the camouflage creams themselves 
until they are happy with the results. The long-term 
prisoner will then complete a record form to be given 
to healthcare.
3. The aim is for a nurse prescriber from healthcare to 
meet with all participants (the intervention group at 
the start and the waitlist control group at the end of 
the research) and write a prescription for 1× camou-
flage cream and 1× camouflage powder. Women will be 
informed that they will only be given one prescription 
for the duration of the study. The amount of camou-
flage cream required will depend on the extent of the 
participant’s scarring, but based on the NWBP pilot20 
we anticipate that one prescription will be enough for 
a 3-month period.
Continued provision of the MSC products after trial 
is not envisaged at this stage within the study prison. 
However, all participants will be given a letter that they 
have the option to give to their general practitioner in the 
community that will detail their MSC prescription, and 
will recommend that the product is prescribed to them.
Assessing feasibility and acceptability
We will assess the feasibility of recruiting and randomising 
women to MSC versus waitlist and of long-term prisoners 
delivering MSC appointments. We will examine use of 
the MSC, attrition (number of dropouts at each time 
point) and retention (the proportion of participants 
who complete the intervention period). The feasibility 
of delivery in a prison setting (ie, location, duration of 
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Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. 
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training, peer delivery) and the acceptability of the inter-
vention to women and staff will be assessed using qual-
itative interviews and focus groups. The feasibility of 
undertaking a full-scale RCT of MSC for women in prison 
will be assessed by studying recruitment (the proportion 
of eligible participants consenting to join the study) and 
completeness of outcome measures at baseline, after 
intervention (approximately 9 weeks from baseline to 
include the time taken to receive the MSC and 6 weeks 
of MSC use) and at follow-up (12 weeks from baseline). 
We have included a 12-week follow-up to assess retention 
and attrition over a longer period of time. Data will be 
collected on reasons for ineligibility, non-consent and 
dropout, including when the participant dropped out/
withdrew from the study.
outcome measures for future rCt design
The aim is that all participants in both groups (MSC and 
waitlist control) will be asked to complete a set of quanti-
tative outcome measures at baseline (0 week), after inter-
vention (approximately 9 weeks later) and at follow-up 
(approximately 12 weeks from baseline). This will help us 
assess the feasibility and acceptability of these measures 
for a future clinical and cost-effectiveness RCT. Outcome 
Table 1 Sections of the training manual
Section No Section name Overview Key learning point
1 Self-harm This section aims to help women 
understand the different forms that self-
harm can take and different reasons why 
women self-harm.
Different people have very different reasons 
for self-harming and it is therefore important 
to not make assumptions.
2 Working with women 
who self-harm in the 
COVER project
This section covers how to manage 
confidentiality and how to work with 
women who self-harm, for example, being 
respectful, don’t judge the participant, the 
limits of confidentiality.
To manage and understand the limits of 
confidentiality, for example, if she discloses 
something that puts her or someone else at 
risk, and what to do if a woman becomes 
upset.
3 Hygiene This section covers how to run a hygienic 
skin camouflage clinic and how to keep the 
kit clean.
Hygiene rules to follow during an 
appointment.
4 Communication This section covers communication rules, 
including how to manage participant 
expectations, for example, setting realistic 
expectations for what MSC can achieve.
Understanding the importance of helping 
the clients to express their wishes and 
working with them to achieve the best 
results.
5 The skin and skin types An overview of preparing the skin for 
application of MSC and how to ensure 
safe usage, for example, by checking for 
allergies.
How to prepare the skin and when it is not 
safe to use the products.
6 Overview of the kit This section describes the items in the MSC 
kits and how to lay them out in a logical 
order.
Laying the kit out in a logical order will 
help the practitioner to quickly identify the 
products.
7 Colour matching This section covers colour matching. 
This will involve some practical activities 
on identifying colour tones and colour 
matching.
To be able to identify tones in the creams 
and perform a colour match.
8 Brush technique An overview of the brush technique and 
when/how to use it.
To understand when and how to use 
brushes.
9 Finger technique An overview of the finger technique and 
when/how to use it.
To understand when and how to use the 
finger technique.
10 Sponge technique An overview of the sponge technique and 
when/how to use it.
To understand when and how to use 
sponges.
11 Spreading technique An overview of the spreading technique and 
when/how to use it.
To understand when and how to use the 
spreading technique.
12 Working with powder An overview of how to use powder to set 
the MSC creams.
To understand the purpose of powder, and 
how to apply it.
13 Completing the record 
card
This section covers how to complete 
the participant record card, including 
what to do with the record card after the 
appointment.
What to include on the record card.
MSC, medical skin camouflage.
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measures will be administered by the project manager 
(PM), trained research assistant (RA) or research nurses 
from the NIHR clinical research network. The PM and 
the RA will be unblinded to the randomisation outcome 
and will therefore only administer baseline measures; 
administration of measures at any other time point by 
these individuals may bias results. The research nurses will 
be blinded and will complete the postintervention and 
12-week follow-up assessments. All research assessments 
(which we anticipate will last approximately 1 hour) will 
take place in a private room in Safer Custody. The PM, 
RA or research nurse will complete a case report form 
for each participant; recording any additional notes on 
each participant, for example, reasons for questionnaire 
non-completion. Given the sensitive nature of some of 
the selected outcome measures, we have consulted with 
women, Safer Custody staff and healthcare/mental health 
staff to develop procedures to protect and support partic-
ipants. If, at any point during a research assessment, the 
woman becomes agitated or distressed, we will ask them if 
they would like to take a break or if they want to resume 
the assessment on another day. If the researcher has any 
concerns for the woman, they will alert the local collab-
orator who will ensure it is dealt with accordingly using 
existing prison support systems. The participant infor-
mation sheet outlines that the researcher is obligated 
to inform the prison if there is a risk to the participant’s 
health, safety or well-being. For this study, this will include 
reporting high suicidal ideation and high risk of serious 
self-harm.
We aim to administer a selection of outcome measures 
(see table 2) to all participants at baseline, 9 weeks and 
12 weeks after baseline. Two of these measures, the 
Dermatology Quality of Life Index (DQLi)23 and Rosen-
berg Self-Esteem Scale (RSES),24 were added following 
focus group discussions on the psychological and inter-
personal impact of scars. At baseline, we also aim to use a 
bespoke demographic and personal history questionnaire 
to collect relevant personal information including age, 
ethnicity, whether they are on remand or sentenced, past 
experience of contact psychiatric services, drug depen-
dence and experiences of domestic violence, sexual abuse 
and parental neglect. We aim to collect this information 
to check whether the two randomised groups have similar 
backgrounds. With women’s permission, our local collab-
orator or a research nurse will access information on key 
forensic and clinical characteristics from CNomis, Syste-
mOne (the prison electronic medical records) and from 
Assessment Care in Custody and Teamwork documenta-
tion; these systems will be accessed by prison staff unless 
the researchers are granted access permission. Forensic 
characteristics will include types of offence (violent or 
non-violent), sentence length and stage of sentence, and 
clinical characteristics will include psychiatric diagnosis 
and history. We aim to administer the Deliberate Self-
Harm Inventory25 at baseline: a 17-item questionnaire 
that assesses the history and frequency of self-harming 
behaviours. We also aim to administer the Zanarini Rating 
Scale for Borderline Personality Disorder (ZAN-BPD) at 
baseline as a measure of borderline psychopathology.26
We aim to examine whether the Warwick-Edinburgh 
Mental Well-Being Scale (WEMWBS)27 is a suitable 
primary outcome for a full-scale RCT. The WEMWBS is 
a 14-item scale of mental well-being covering subjective 
Table 2 Participant assessment schedule
Assessment tool Brief description
Time point
Duration 
(min) Baseline Postintervention 3 months
Personal history questionnaire Sociodemographic/life history 5 X
DSHI Methods/history of self-harm 10 X
WEMWBS Mental well-being 5 X X X
BSS Suicidal ideation 10 X X X
BDI-II Depression 10 X X X
BHS Hopelessness 5 X X X
DQLi Self-harm scarring quality of life 5 X X X
RSES Self-esteem 5 X X X
Zanarini Rating Scale Borderline personality disorder 5 X
EQ-5D-5L Generic health 5 X X X
SF-12 Generic health/quality of life 5 X X X
Qualitative interview Acceptability and feasibility 30 X
Total time burden 70 65 95
Self-harm diary Self-harm thoughts and incidents Weekly from baseline to 3 months
BDI-II, Becks Depression Inventory II; BHS, Beck Hopelessness Scale; BSSI, Becks Scale for Suicidal Ideation; DQLi, Dermatology Quality of Life 
Index; DSHI, Deliberate Self-Harm Inventory; EQ-5D-5L, EuroQol Five-Dimensional Questionnaire, Five-Level Version; RSES, Rosenberg Self-
Esteem Scale; SF-12, 12-Item Short-Form Health Survey; WEMWBS, Warwick-Edinburgh Mental Well-Being Scale; ZAN-BPD, Zanarini Rating 
Scale for Borderline Personality Disorder.
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well-being and psychological functioning, in which all 
items are worded positively and address aspects of positive 
mental health. The WEMWBS has high internal consis-
tency (α=0.91) and test–retest reliability (0.83).27 This 
measure would be used to calculate study power in a full-
scale subsequent trial.
Becks Scale for Suicidal Ideation (BSS)28: a 19-item 
instrument measuring intensity, duration and specificity 
of thoughts about committing suicide. The BSS has high 
internal consistency (0.89) and high inter-rater reliability 
(0.83).28 The BSS has been successfully used in a pilot 
trial of Psychodynamic Interpersonal Therapy for women 
prisoners who self-harm.22
Becks Depression Inventory (BDI-II)29: a 21-item scale 
measuring symptoms of depression. The BDI-II has high 
internal consistency and a test-retest reliability ranging 
from 0.73 to 0.96.30
Beck Hopelessness Scale (BHS)31: a 20-item self-report 
inventory designed to measure three major aspects of 
hopelessness: feelings about future, loss of motivation 
and expectations. The BHS has high concurrent validity 
(0.86) and high reliability (α=0.91).31
Prison-adapted DQLi23: a 7-item questionnaire adapted 
from a validated 10-item scale that has been used in over 
40 different skin conditions in over 80 countries. Test–
retest reliability has been found to be high (0.99).23
RSES24: a 10-item Likert scale with items answered on 
a 4-point scale—from strongly agree to strongly disagree. 
The scale measures self-esteem and has been used in 
prison research.32 Internal consistency ranges from 0.77 
to 0.88 and test–retest reliability ranges from 0.82 to 
0.85.24
EuroQol Five-Dimensional Questionnaire, Five-Level 
Version (EQ-5D-5L)33: a generic preference-based 
measure covering five domains of health-related quality 
of life (mobility, self-care, usual activities, pain/discom-
fort, anxiety/depression). Test–retest reliability is high 
and ranges from 0.78 to 0.87, with convergent validity at 
0.64.34
12-Item Short-Form Health Survey (SF-12) is a short-
ened version of the SF-36,35 consisting of 12 questions 
covering eight dimensions of health: physical functioning, 
role limitations—physical, bodily pain, general health, 
vitality, social functioning, role limitations—emotional, 
and mental health. Test–retest reliability ranges from 0.76 
to 0.89 and relative validity ranges from 0.43 to 0.93.34
To reduce attrition, we aim to seek consent at baseline 
for women who have been transferred or have left prison 
during the study period to be followed up in person at 
other prisons or in a public place in the community, 
following a lone worker policy.
In addition to the outcome measures listed above, we 
also aim to ask trial participants to complete a weekly 
diary every week from their baseline assessment. Prison 
staff and women prisoners in the phase 1 focus groups 
proposed the use of a weekly diary; some of the women 
had completed a diary of self-harm thoughts and events 
in the past and found it helpful. The research team will 
collect the diary each week. The diary will ask questions 
about any thoughts or acts of self-harm that have occurred 
during the week and any life events that have impacted 
on their self-harm during the week. Women will also have 
a free-text space to add additional comments.
We also aim to pilot the collection of resource use data 
so that we can determine if it is feasible to gather these data 
in a larger trial, with a view to calculating the cost of treat-
ment in comparison to usual care. This will be collected 
using the Secure Facilities Service Use Schedule36 and a 
bespoke resource use questionnaire. Resource use data are 
likely to be extracted by the local collaborator from systems 
such as CNomis and Officers logs. Prison staff will redact any 
confidential information. We also aim to use these systems, 
together with SystmOne, to extract data on self-harm inci-
dents that occurred during the intervention. If we success-
fully extract the data we will then triangulate prison records 
of self-harm incidents with women’s self-reported incidents. 
We will record the time taken by prison staff and healthcare 
staff to extract this information.
To inform a future cost analysis, we also aim to record 
the time spent by Changing Faces training the researchers 
in MSC, time spent by the research team training long-
term prisoners to become skin camouflage practitioners, 
time spent by long-term prisoners delivering the interven-
tion and quantities of MSC products prescribed.
Qualitative data
We aim to conduct interviews with all women in the MSC 
group (n=20) at the end of the study, to assess the accept-
ability of the intervention to service users. The interviews 
with women will explore their views on applying MSC, 
how long it stays on for, how useful they found it and any 
positive or negative effects on their everyday life, mood, 
self-esteem and self-confidence. The topic guides have 
been developed in consultation with two service user 
researchers and informed by outcomes of the phase 1 
focus group.
We also aim to interview the long-term prisoners to 
assess their experiences of being an MSC practitioner, 
in terms of the acceptability of the training, mentoring/
support from the research team and any benefits or diffi-
culties working with participants.
In addition, we aim to conduct a focus group with 
prison staff from different disciplines (including Safer 
Custody staff, prison officers and healthcare staff) 
that have been in contact with women involved in the 
trial. The focus group would explore acceptability of 
the intervention from a staff perspective, including 
what they thought about prisoner delivery of the MSC 
intervention and whether the intervention has had a 
positive, or negative, impact on their job or their rela-
tionships with women prisoners. All interviews and the 
focus group will use semistructured topic guides with 
open-ended questions that should enable us to explore 
in-depth the aspects of the intervention that worked 
well, the aspects that did not work well and things that 
could be improved. With permission from participants, 
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interviews will be audio recorded. All recordings will 
then be transcribed verbatim and analysed using 
thematic analysis.37
We aim to assess fidelity to the MSC intervention by (A) 
observing the long-term prisoners at the end of training 
covering one of our service user researcher’s scars, 
and (B) audio recording 10% of the training sessions 
which will be rated for fidelity to the training manual by 
an independent researcher.
data analysis
Quantitative analyses
We shall compare means before and after treatment using 
descriptive statistics, including SDs and CIs for outcome 
variables to inform sample size estimates for a future RCT. 
We will also present descriptive statistics on recruitment 
and retention of participants in both groups, including 
reasons for dropout at different stages.
We shall assess the feasibility and relevance of both the 
EQ-5D-5L and SF-12 for the prison population through 
correlation between changes from baseline to follow-up 
of these and other piloted measures (WEMWBS, BSS, 
BDI, BHS, RSES); and examination of completion rates. 
Descriptive analysis of health-related quality of life data 
will also inform the suitability of the measures for future 
clinical and economic evaluations of the intervention.
Resource use collection will also be assessed through 
time taken to complete questionnaires, completion rates 
and ability to obtain included resource use categories to 
inform suitability of resource use categories in a future 
economic evaluation. Descriptive analysis of resource use 
data will also inform future trial design.
Qualitative data
Qualitative data will be analysed using thematic analysis37; 
analysis which will be conducted by the RA and PM and 
checked for accuracy by an independent researcher. 
Preliminary codes and categories are assigned to the 
text38 and emergent themes subject to constant compar-
ison and examined for goodness of fit until a final set 
of key themes identified.39 Adopting an inductive, itera-
tive approach, data analysis will commence with the first 
interview.
data entry and storage
Written consent forms and completed questionnaires 
will be removed straight to the University of Manchester. 
Participants will be given a unique participant number 
that will be used on questionnaires and the electronic 
database. A password-protected document will link partic-
ipant names and numbers. Any identifying personal data 
(eg, consent forms) will be stored separately from other 
research data. In the University of Manchester this will 
mean storage in the locked limited access corridor. Elec-
tronic databases will be stored on an encrypted space on 
University of Manchester computers. The RA would enter 
all data and the PM will carry out 10% checks for accuracy.
EthICs And dIssEMInAtIon
Ethical approval for COVER was granted by the North 
East–York REC for phases 1 and 2 (reference: 16/
NE/0030) and West of Scotland REC 3 for phases 3 and 4 
(reference: 16/WS/0155).
Adverse events
All participants will be women who have a history of self-
harm. Therefore, self-harm incidents are an expected 
event and not necessarily a serious adverse event. All 
adverse events, including incidents of self-harm, will be 
recorded and reported to the PM. In consultation with 
prison staff and the prisoner, the research team will assess 
the seriousness of the adverse event and whether it is 
related to project participation; events that are judged as 
serious and unrelated will be reported to the sponsor only. 
Events judged as serious and related to project participa-
tion will be reported to the research sponsor, host NHS 
trust and West of Scotland REC.
dissemination
We aim for our findings to be disseminated to prisoners, 
prison staff and to the wider stakeholder (academic and 
clinical) community via showcase events at the study 
prison, presentations at national and international confer-
ences, journal publications, safer custody and prison 
governor meetings and university/NHS trust communi-
cations. During dissemination, we will hold discussions 
with key personnel from NHS England and Her Majesty's 
Prison and Probation Service (HMPPS) regarding future 
provision of the intervention.
dIsCussIon
Despite the large number of women in prison who self-
harm (or who have self-harmed in the past and are 
living with scarring), there are little/no evidence-based 
interventions which aim to improve self-esteem, confi-
dence and well-being. This low-cost intervention has 
the potential to improve women’s mood and how they 
feel about themselves.
Our phase 1 focus groups suggested that many 
women prisoners who repeat self-harm struggle on a 
regular basis with negative feelings about their scars, 
for example, they have to cover them in front of others/
family for fear of being judged adversely or upsetting 
them; they are a constant reminder of bad times or they 
lack confidence in their bodies because of scars. A pris-
oner-delivered MSC intervention could reduce such 
distress women prisoners experience and help them 
reintegrate into the community without the additional 
burden of being judged because of their scars.
This intervention was implemented successfully in a 
community mental health service. We, therefore, antici-
pate that, with the support of prison staff and long-term 
prisoners, COVER will provide a beneficial resource to 
improve well-being in an often-neglected population.
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Engaging long-term prisoners in the delivery of 
MSC clinics should increase the sustainability of the 
intervention if it were to be commissioned in future 
and provide meaningful work for women prisoners, 
offering a valuable opportunity to improve relation-
ships between prisoners and contribute towards a 
therapeutic community with the prison. Peer support 
schemes, such as the Samaritan’s Listener scheme 
which runs across many UK prisons, are increasingly 
popular, enabling prisoners to develop a range of 
transferable skills and reducing the burden of distress 
and self-harm management for prison staff. If success-
fully implemented, COVER will run alongside these 
peer support services and provide additional help for 
women who self-harm.
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